Takeda UK announced today that all sales teams and support resource will be integrated into the company effective 1 st June 2016.
The field sales teams have been operated and managed by Ashfield Healthcare since 2004. This announcement impacts over 70 team members of the Oncology Key Account Manager (KAM) team, Inflammatory Bowel Disease (IBD) KAM team and the entire General Medicine Regional Account Director (RAD) and Customer Account Specialist (CAS) teams.
These team members will transition to become Takeda employees from 1st June, 2016 following the conclusion of a consultation and transition process in line with legislative requirements.
This move will nearly double the number of Takeda employees in the UK and is part of an ambitious growth strategy to become an agile, specialty care provider focused on specific opportunities in Oncology, IBD and Diabetes.
Adam Zaeske, Managing Director, Takeda UK & Ireland said: “Takeda and Ashfield Healthcare were pioneers when the RAD/KAM model was conceived in 2004. The partnership has been a tremendous success and is still recognised with many major companies adopting a similar approach.”
“Today Takeda is at the cusp of a significant growth phase with specific opportunities in Oncology, IBD and Diabetes. We have made the strategic decision to integrate our sales teams as we recognise the critical role they play in growing our business and continuing to build a strong organisation.”
“This is an incredibly exciting time for Takeda as we transform our business as an agile, specialty care provider. This announcement is about forging one integrated team and is the latest step in that journey.”
“I sincerely thank our partners at Ashfield Healthcare for their hard work and support over the years. This announcement is a validation of Ashfield’s ability to help build healthcare companies and propel them forward through expertise and ingenuity. Takeda UK is strong today in large measure because of our partnership with Ashfield Healthcare.”
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.